Parexel International (ma) Corporation
Location
Massachusetts
Founded
1983-02-28
Website
Risk Signals
455 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Parexel International (ma) Corporation
Live alerts from global media, monitored by Business Radar
2021-07-02 (wraltechwire.com)
Durham CRO Parexel will be acquired for $8.5B
In a deal worth $8.5 billion, the private-equity-backed CRO Parexel will be acquired by another private equity firm.
Read more
2012-07-19 (prnewswire.com)
PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced it is the first...
Read more
(financierworldwide.com)
EQT and Goldman acquire Parexel for $8.5bn —
Four years after initially being taken private by Pamplona Capital Management LP, global clinical research organisation Parexel is being acquired again – this time by EQT IX fund and the private equity (PE) business within Goldman Sachs Asset Management, in a deal valued at $8.5bn.
Read more